Trinity Partners, LLC (Trinity Life Sciences)

Trinity Life Sciences is a strategic, tech-enabled commercialization company dedicated to empowering pharmaceutical, biotechnology, and medtech organizations. The firm's core business involves advancing the development, launch, and optimization of new medical innovations through a fusion of human and artificial intelligence. Headquartered in Waltham, Massachusetts, Trinity Life Sciences aims to be a leading force in the future of life sciences commercialization.

The company provides a comprehensive suite of solutions, including advisory services, insights and analytics, and technology. Key offerings span strategic planning and forecasting, value, access, and pricing strategies, integrated insights, launch planning and execution, and customer engagement. Trinity Life Sciences also specializes in commercial strategy, corporate and portfolio strategy, new product planning, competitive intelligence, brand and marketing strategy, patient centricity, evidence strategy (HEOR), market research, and industry benchmarking reports. These services cater to both emerging biotech firms and established pharmaceutical companies.

In November 2025, Scott Evangelista was appointed Chief Executive Officer, succeeding Leslie Orne. Trinity Life Sciences is recognized for its leadership in integrating human and artificial intelligence within life sciences commercialization. The firm was named one of Forbes World's Best Management Consulting Firms in 2026 and received the Platinum Pinnacle Award for Best Use of AI Technology in July 2026. Trinity Life Sciences is majority-owned by Kohlberg & Company, which acquired the firm in 2021, and received a minority investment from Bain & Company in 2022.